Podcasts about Memorial Sloan Kettering Cancer Center

In today's episode, we spoke with Michael J. Mauro, MD, an attending physician at Memorial Sloan Kettering Cancer Center in New York, New York.In our exclusive interview, Dr Mauro discussed the vast assortment of TKIs available for the treatment of patients with chronic myeloid leukemia (CML). In addition to breaking down numerous different TKIs that he turns to in clinical practice and their accompanying data, Mauro also dissected the November 2025 FDA approval of generic dasatinib (Phyrago) tablets for patients with CML and acute lymphoblastic leukemia. More specifically, Mauro outlined what this approval means for patients who need concomitant gastric acid–reducing agents like proton pump inhibitors.

In this episode of the Award-winning PRS Journal Club Podcast, 2026 Resident Ambassadors to the PRS Editorial Board – Lucas Harrison, Christopher Kalmar, and Priyanka Naidu- and special guest, Andrea L. Pusic, MD, discuss the following articles from the May 2026 issue: "Cost of Care and Surgical Outcomes between Direct-to-Implant and Staged Tissue Expander Breast Reconstruction" by Chakraborty, Bouhadana, Bernstein et al. Read the article for FREE: https://bit.ly/DTI_TE_Comparison Dr. Andrea L. Pusic is our special guest. She serves as Chief of Plastic and Reconstructive Surgery at Brigham and Women's Hospital, Director of Patient-Reported Outcomes, and the Joseph Murray Professor of Surgery at Harvard Medical School. Dr. Pusic also holds a Master of Public Health from Johns Hopkins University. She completed her general surgery residency at Dalhousie University, followed by a plastic surgery residency at McGill University and a microsurgery fellowship at Memorial Sloan Kettering Cancer Center. Her clinical practice focuses on breast reconstruction and aesthetic breast surgery, including both autologous tissue reconstruction and implant-based techniques, with a strong emphasis on individualized, patient-centered care and quality-of-life outcomes. An internationally recognized leader in patient-reported outcomes research, Dr. Pusic has authored more than 200 publications. She developed the BREAST-Q, a widely used instrument for measuring patient satisfaction and quality of life after breast surgery. She also co-led the NCI-funded Mastectomy Reconstruction Outcomes Consortium, a multi-institutional collaboration across 11 centers studying patient perspectives on breast reconstruction. Dr. Pusic now leads the PROVE Center, where she advances the use of patient-reported outcomes to improve surgical quality, patient experience, and healthcare value. READ the articles discussed in this podcast as well as free related content: https://bit.ly/JCMay26Collection

In today's episode, we welcomed Pedram Razavi, MD, PhD, and Dara S. Ross, MD. Dr Razavi is a breast medical oncologist and director of Liquid Biopsy & Genomics at Memorial Sloan Kettering Cancer Center in New York, New York. Dr Ross is an associate attending pathologist at Memorial Sloan Kettering Cancer Center.In our exclusive interview, Drs Razavi and Ross discussed the evolution of ESR1 mutation–directed breast cancer management, emphasizing the role of comprehensive genomic testing at metastatic recurrence, including liquid biopsy and tissue sequencing. They highlighted that ESR1 mutations can develop in patients receiving aromatase inhibitors and that the detection of these mutations is crucial for treatment decisions. They also highlighted findings from the phase 3 SERENA-6 trial (NCT04964934), which tested switching to camizestrant upon the emergence of an ESR1 mutation during treatment with an aromatase inhibitor and a CDK4/6 inhibitor ahead of radiographic disease progression in patients with hormone receptor–positive, HER2-negative metastatic breast cancer. Despite concerns from the FDA's Oncologic Drugs Advisory Committee (ODAC) about SERENA-6's design and overall survival outcomes, the experts praised the trial's innovative approach to personalizing breast cancer management based on biomarkers and noted ways that the ODAC decision may affect future clinical research in this field.

Welcome to the Oncology Brothers podcast! In this episode, we dived deep into the world of BRAF V600E-driven non-small cell lung cancer (NSCLC) with our guest Dr. Gregory Riely, a thoracic medical oncologist from Memorial Sloan Kettering Cancer Center. Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o Apple Podcast: https://podcasts.apple.com/us/podcast/oncology-brothers-practice-changing-cancer-discussions/id1653340966 Follow us on social media: ⁠X/Twitter: https://twitter.com/oncbrothers ⁠Instagram: https://www.instagram.com/oncbrothers Website: https://oncbrothers.com/ Join us as we explore: The prevalence of BRAF V600E mutations in NSCLC and how they compare to other oncogenic drivers. The latest treatment options, including BRAF-MEK inhibitors like Encorafenib-Binimetinib and Dabrafenib-Trametinib. Key clinical trial data that led to the approval of these therapies and their implications for patient care. The role of immunotherapy in treating BRAF V600E patients and how to effectively sequence treatments. Patient characteristics that influence treatment decisions, including smoking history and PD-L1 expression. Whether you're a practicing oncologist or simply interested in the latest advancements in cancer treatment, this episode is packed with valuable insights and expert opinions. Don't miss it! Subscribe to our channel for more discussions on oncology and stay updated on the latest in cancer care! #BRAFV600E, #NSCLC, #BRAFMEKinhibitor, #TargetedTherapy, #OncologyBrothers

Dr. Freddy Nguyen, a physician-scientist-entrepreneur and Director of MIT's Catalyst Scholars Program, discusses his work at the frontier of translational research, diagnostics, precision medicine and healthcare innovation with Pit HexAI host Jordan Gass-Poore' and his involvement in co-founding Nine Diagnostics, a startup spun out of Memorial Sloan Kettering Cancer Center.Focusing on innovation in precision medicine, Dr. Nguyen traces his path through initiatives like MIT Hacking Medicine and the MIT Catalyst Scholars Program and his work helping teams identify and turn real clinical problems into projects designed to reach patients. Emphasizing patient‑first and science‑first approaches to innovation, Dr. Nguyen encourages students and collaborators to ask why things work the way they do and to build solutions that can move quickly from lab to clinic. That same mindset underpins Nine Diagnostics, which uses a high‑throughput nanosensor platform to generate molecular “fingerprints” of disease. Instead of tracking a few isolated biomarkers, these fingerprints capture complex patterns across thousands of molecules, reflecting both tumor biology and the broader physiological context of each patient. This shift from genomics alone to “functional precision medicine” enables clinicians and researchers to see what is happening in real time inside the body, monitor treatment response faster and tailor therapies more precisely to each patient.Touching on how AI and machine learning are making these technologies clinically useful, Dr. Nguyen discusses how advanced algorithms integrate multimodal data streams to discover patterns that would be impossible to detect by eye. These models not only improve sensitivity and specificity when predicting treatment response, but also support emerging “digital twin” computational representations of patient health that can be used to simulate and optimize care. At the same time, he emphasizes that more data is not automatically better, and that explainable AI in healthcare must focus on which signals truly matter for a specific clinical decision and how to close the loop between model outputs and underlying biology.For students and early‑career researchers, Dr. Nguyen shares practical guidance on getting involved in leveraging AI to advance precision medicine and designing research with translation in mind from day one so that innovations reach patients faster, rather than staying trapped in academic silos.

In this episode of the Award-winning PRS Journal Club Podcast, 2026 Resident Ambassadors to the PRS Editorial Board – Lucas Harrison, Christopher Kalmar, and Priyanka Naidu- and special guest, Andrea L. Pusic, MD, discuss the following articles from the May 2026 issue: "Single versus Multiple Perforator Flaps in Autologous Breast Reconstruction: A Regression Analysis of Clinical Outcomes and Financial Metrics" by DeVito, Ke, Wen, et al. Read the article for FREE: https://bit.ly/MutliperfAutoBreast Dr. Andrea L. Pusic is our special guest. She serves as Chief of Plastic and Reconstructive Surgery at Brigham and Women's Hospital, Director of Patient-Reported Outcomes, and the Joseph Murray Professor of Surgery at Harvard Medical School. Dr. Pusic also holds a Master of Public Health from Johns Hopkins University. She completed her general surgery residency at Dalhousie University, followed by a plastic surgery residency at McGill University and a microsurgery fellowship at Memorial Sloan Kettering Cancer Center. Her clinical practice focuses on breast reconstruction and aesthetic breast surgery, including both autologous tissue reconstruction and implant-based techniques, with a strong emphasis on individualized, patient-centered care and quality-of-life outcomes. An internationally recognized leader in patient-reported outcomes research, Dr. Pusic has authored more than 200 publications. She developed the BREAST-Q, a widely used instrument for measuring patient satisfaction and quality of life after breast surgery. She also co-led the NCI-funded Mastectomy Reconstruction Outcomes Consortium, a multi-institutional collaboration across 11 centers studying patient perspectives on breast reconstruction. Dr. Pusic now leads the PROVE Center, where she advances the use of patient-reported outcomes to improve surgical quality, patient experience, and healthcare value. READ the articles discussed in this podcast as well as free related content: https://bit.ly/JCMay26Collection

Dr. Jonathan Howard (neurologist and author) and science journalist Wendy Orent return for another sharp, unsparing look at the state of U.S. public health policy. In this episode, the hosts unpack the surprise withdrawal of Casey Means as surgeon general nominee, her replacement by Fox News commentator and MSKCC breast imaging chief Dr. Nicole Saphier, and what the shuffle signals about the fracturing of the MAHA coalition. They dig into Saphier's contradictory record — pro-vaccine statements from 2020 and 2021 set against more recent anti-vaccine messaging, her supplement business (DropRx), and her now-deleted social media posts criticizing Trump and Elon Musk. From there, the conversation turns to the FDA's blocked publication of research showing the COVID and shingles vaccines are safe, the apparent role of former FDA vaccine office chief Dr. Vinay Prasad, and reporting that FDA Commissioner Marty Makary's job is in jeopardy. The episode also covers a small piece of good news — NIH program director Jenna Norton being reinstated after Jay Bhattacharya placed her on administrative leave for organizing the Bethesda Declaration — alongside disturbing developments: RFK Jr. clearing the path for minors to use tanning beds, and the militarized arrest of 78-year-old retired NIH scientist Dr. David Morens. Howard and Orent close on what the Morens arrest reveals about where lab leak conspiracy thinking has led American science and the rule of law. Hosts Dr. Jonathan Howard: Neurologist, professor, and author who writes prolifically on COVID misinformation and public health policy. Wendy Orent: Science journalist and author specializing in infectious disease, evolutionary biology, and public health. Episode Timestamps [00:00] Welcome and Atlanta weather check-in [00:35] Casey Means out, Nicole Saphier in as surgeon general nominee — what it signals about MAHA [01:30] Saphier's role at Memorial Sloan Kettering and her integrative medicine push [02:50] The 2021 WSJ op-ed with Marty Makary: a 10-fold error on pediatric COVID hospitalizations that was never corrected [06:30] Saphier's video opposing COVID vaccines for healthy children — and the framing of myocarditis as a fate worse than death [09:20] Saphier's earlier pro-vaccine statements from 2020 and 2021, and why MAHA now resents her [11:15] DropRx supplements: the surgeon general nominee's tincture business [12:30] Brandy Zadrozny's reporting on Saphier's book and her past criticism of the Plandemic film [13:10] Wendy watches Plandemic so you don't have to: Judy Mikovits and the anti-vaccine machine [14:50] CNN reports Saphier purged posts critical of Trump and Musk before her nomination [15:50] The most disturbing Saphier clip: 'DOGE is one of the greatest things to happen in U.S. history' while telling cancer researchers to 'just pause' [16:50] Harvard's November 2025 finding: hundreds of thousands of deaths from the USAID shutdown [18:20] Good news: Jenna Norton reinstated at NIH after Jay Bhattacharya tried to fire her over the Bethesda Declaration [19:30] Greg Gonsalves on scientists who cooperate with authoritarian science policy [20:10] FDA blocked publication of research showing the COVID and shingles vaccines are safe [21:30] Vinay Prasad: the censorship critic who became a censor [22:30] Why are these people opposed to the shingles vaccine? Howard and Orent on herpes zoster, strokes, and ophthalmic complications [23:50] New evidence: recombinant zoster vaccine linked to reduced dementia risk in adults 65+ [26:10] Marty Makary's FDA in chaos — WSJ, Bloomberg, and Politico reporting on a possible shakeup [28:00] Trump pressures the FDA to approve flavored vapes; ENDS authorization issued the same day [31:00] Makary's interview defending the Replimmune metastatic melanoma rejection — and getting caught in the contradiction [33:30] Who's really driving the FDA shakeup? Biotech investors, not patients [35:30] RFK Jr. clears path for minors to use tanning beds, and what dermatologists are saying [36:30] The arrest of Dr. David Morens: a 78-year-old retired NIH scientist, federal agents, tactical gear, and a strip-search [38:30] Lysenkoism revisited — what the lab leak conspiracy was always going to lead to [40:30] Closing thoughts and sign-off Key Discussion Points The Nicole Saphier Nomination Casey Means was withdrawn as surgeon general nominee and replaced by Dr. Nicole Saphier, head of breast imaging at Memorial Sloan Kettering Cancer Center and a frequent Fox News medical commentator. Howard revisits Saphier's December 2021 Wall Street Journal op-ed with Marty Makary, which understated pediatric COVID-19 hospitalizations by roughly a factor of 10 because the authors did not realize covid.net data only covered about 10 percent of the U.S. population. The error has never been corrected. Saphier's pre-nomination digital footprint included pro-vaccine statements from 2020 and 2021 alongside more recent anti-vaccine content, criticism of Trump and Elon Musk that has since been purged, and a personal supplement line called DropRx. FDA Censorship of Vaccine Safety Research The FDA blocked publication of internal research finding that the COVID-19 and shingles vaccines are safe, with reporting suggesting Dr. Vinay Prasad's office was involved in the decision before he left the agency. Howard points out the irony: Prasad built much of his public profile complaining about scientific censorship, then engaged in censorship the moment he held FDA power. New peer-reviewed research continues to show the recombinant zoster (shingles) vaccine is associated with reduced dementia risk in adults aged 65 and older, even as senior officials downplay or block such findings. Marty Makary on Thin Ice Multiple outlets — the Wall Street Journal, Bloomberg, NOTUS, and a Rachel Bade scoop — report Makary is at risk of being removed as FDA Commissioner over conflicts with the White House and his handling of rare-disease drug approvals. The same day Trump publicly pressured the FDA on flavored vapes, the agency issued a press release authorizing new ENDS (electronic nicotine delivery systems) products. In a 15-minute interview, Makary defended the rejection of Replimmune's metastatic melanoma drug by attributing it to career FDA scientists, but the journalist surfaced earlier indications that the initial review team had recommended approval. A Rare Piece of Good News NIH program director Jenna Norton, a key organizer of the Bethesda Declaration, was reinstated after Dr. Jay Bhattacharya placed her on administrative leave. A judge also reinstated several FEMA employees in the same ruling. The Arrest of Dr. David Morens Federal agents in tactical gear and bulletproof vests arrested Dr. David Morens, a 78-year-old retired NIH influenza researcher and former aide to Dr. Anthony Fauci, at his home over allegations he used a private email account to discuss official business and avoid FOIA disclosure. According to reporting in Science, Morens was strip-searched, handcuffed, and driven roughly 65 kilometers for fingerprinting and booking. Howard and Orent frame the arrest as the predictable endpoint of years of lab leak conspiracy rhetoric, and as a clear case of selective political prosecution. Mentioned in This Episode Wall Street Journal op-ed: 'Should You Vaccinate Your Five-Year-Old?' by Nicole Saphier and Marty Makary, December 3, 2021 Plandemic (2020 anti-vaccine film featuring Judy Mikovits) Make America Healthy Again (book by Nicole Saphier) Harvard study, November 2025, on deaths attributable to the USAID shutdown Greg Gonsalves essay on Vichy scientists Bethesda Declaration Alyssa Finley, Wall Street Journal: 'President Trump's Marty Makary Problem' Bloomberg: 'Paranoia, Turmoil and Backlash Inside Marty Makary's FDA' Rachel Bade: 'Scoop: Makary's Job in Jeopardy as White House Considers FDA Shakeup' Liz Esely White, Wall Street Journal: 'Trump Pressures FDA Commissioner to Approve Flavored Vapes' Los Angeles Times: 'RFK Jr. clears path for minors' use of tanning beds, much to the dismay of dermatologists' Science: 'Guns and bulletproof vests: How federal agents arrested a Fauci aide' Brandy Zadrozny — reporting on Nicole Saphier

Host Holly Wayment brings us Houston spine surgeon Rex Marco who, after a terrible cycling accident , faced  life-changing paralysis to recovery through mindfulness, the RAIN method, and radical acceptance.   He describes what happened to him and how in one moment everything can change. His work now explores how compassion, mindfulness, and vulnerability can reshape how we live, lead, and heal. In 2019, Dr. Marco sustained a C3–4 fracture-dislocation in a cycling accident, resulting in C2 quadriplegia. Today, he serves as the Chief Medical Ambassador for the Christopher & Dana Reeve Foundation, advocating for research, cure, and improved quality of life for individuals living with spinal cord injury. He is also a certified mindfulness meditation teacher and is passionate about integrating resilience, presence, and emotional healing into medicine, leadership, and life. He's known for creative and transformative teaching and shares that his most profound transformation came through recovery, where he confronted longstanding patterns in how he related to himself and others.  This episode explores how he says acceptance, gratitude, and recovery programs transformed his leadership, clinical practice, and family life, offering actionable tools for cultivating presence and emotional safety. Dr. Rex Marco is an internationally recognized orthopedic spine and musculoskeletal oncology surgeon whose career has centered on caring for patients with complex spinal disorders and tumors. He completed his undergraduate studies at UC Irvine and conducted research at the National Institutes of Health through the Howard Hughes Medical Institute before earning his medical degree from the UCLA School of Medicine. He went on to complete surgical training at Virginia Mason Medical Center, orthopedic residency at UC Davis, and dual fellowships in musculoskeletal oncology at Memorial Sloan Kettering Cancer Center and reconstructive spine surgery at Rush University. Dr. Marco has held leadership roles at MD Anderson Cancer Center, Texas Children's Hospital, Houston Methodist Hospital, and UTHealth Houston, where he serves as Spine Fellowship Director.  

Updates in US Food and Drug Administration approvals for poly-ADP-ribose polymerase inhibitors in Ovarian Cancer: A society of gynecologic oncology clinical practice reviewModerator:Ursula A. Matulonis, MD; Dana-Farber Cancer InstituteSpeakers:Bhavana Pothuri, MD; Perlmutter Cancer Center, NYU Langone HealthRóisín E. O'Cearbhaill, MD; Gynecologic Medical Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center; Department of Medicine, Weill Cornell Medical CollegeYvette Drew, MBBS, PhD; BC Cancer Centre Vancouver and University of British ColumbiaChristina Washington, MD; Stephenson Cancer Center, University of OklahomaUrsula A. Matulonis, MD, is joined by Bhavana Pothuri, MD, Róisín O'Cearbhaill, MD, Yvette Drew, MBBS, PhD, and Christina Washington, MD, to discuss recent updates in US Food and Drug Administration approvals for poly-ADP-ribose polymerase inhibitors (PARPi) in ovarian cancer. Based on the recent Society of Gynecologic Oncology clinical practice review published in Gynecologic Oncology, the speakers review the evolving role of PARP inhibitors and the clinical implications of updated regulatory approvals.The panel explores current evidence supporting PARP inhibitor use in ovarian cancer, including considerations for patient selection, biomarker testing, maintenance therapy, and safety considerations. The speakers also discuss how recent changes in FDA indications may affect clinical decision-making and treatment sequencing in practice.This podcast highlights practical clinical pearls to help guide practitioners in the appropriate integration of PARP inhibitors into the management of ovarian cancer patients.This podcast was developed by the Society of Gynecologic Oncology for Gynecologic Oncology.Check out more content on the journal's homepage  at https://www.gynecologiconcology-online.net

In this episode of the Award-winning PRS Journal Club Podcast, 2026 Resident Ambassadors to the PRS Editorial Board – Lucas Harrison, Christopher Kalmar, and Priyanka Naidu- and special guest, Andrea L. Pusic, MD, discuss the following articles from the May 2026 issue: "Prepectoral versus Subpectoral Implant-Based Breast Reconstruction: Evaluating the Shift" by Cordray, Khan, Voytik, et al. Read the article for FREE: https://bit.ly/PrePecVSSubPec Dr. Andrea L. Pusic is our special guest. She serves as Chief of Plastic and Reconstructive Surgery at Brigham and Women's Hospital, Director of Patient-Reported Outcomes, and the Joseph Murray Professor of Surgery at Harvard Medical School. Dr. Pusic also holds a Master of Public Health from Johns Hopkins University. She completed her general surgery residency at Dalhousie University, followed by a plastic surgery residency at McGill University and a microsurgery fellowship at Memorial Sloan Kettering Cancer Center. Her clinical practice focuses on breast reconstruction and aesthetic breast surgery, including both autologous tissue reconstruction and implant-based techniques, with a strong emphasis on individualized, patient-centered care and quality-of-life outcomes. An internationally recognized leader in patient-reported outcomes research, Dr. Pusic has authored more than 200 publications. She developed the BREAST-Q, a widely used instrument for measuring patient satisfaction and quality of life after breast surgery. She also co-led the NCI-funded Mastectomy Reconstruction Outcomes Consortium, a multi-institutional collaboration across 11 centers studying patient perspectives on breast reconstruction. Dr. Pusic now leads the PROVE Center, where she advances the use of patient-reported outcomes to improve surgical quality, patient experience, and healthcare value. READ the articles discussed in this podcast as well as free related content: https://bit.ly/JCMay26Collection

Welcome to the third episode of our three-part series on colorectal cancer! In this episode of the Oncology Brothers we are joined by Dr. Rona Yaeger, a medical oncologist from the Memorial Sloan Kettering Cancer Center. Together, we dived into the management of common side effects associated with systemic treatments for colorectal cancer. Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o Apple Podcast: https://podcasts.apple.com/us/podcast/oncology-brothers-practice-changing-cancer-discussions/id1653340966 Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ Episode Highlights: • Overview of 5-FU and capecitabine, including the importance of DPYD mutation testing and side effects like cytopenia, mucositis, and cardiac toxicity. • Discussion on the use of 5-FU bolus in both metastatic and adjuvant settings. • Insights into managing oxaliplatin-induced neuropathy and the potential benefits of oral cryotherapy. • Clinical pearls for irinotecan, including the management of diarrhea and cholinergic effects. • Considerations for using Bevacizumab, including risks of hypertension, proteinuria, and blood clots. • Tips for managing side effects of anti-EGFR agents like Cetuximab and Panitumumab, including rash and infusion reactions. • An overview of oral agents such as encorafenib, TAS-102, and Regorafenib, with a focus on dosing strategies and side effect management. Join us as we explore these critical topics and provide valuable insights for healthcare professionals managing colorectal cancer treatments. Don't forget to subscribe for more episodes! #ColorectalCancer, #SideEffectManagement, #DPYDtesting, #ChemotherapyToxicity, #SupportiveCare

Je reçois le Dr Cloé Brami, cancérologue, enseignante chercheur, soignante engagée et fondatrice de "Mû Médecine", l'école de médecine intégrative. 

Je reçois le Dr Cloé Brami, cancérologue, enseignante chercheur, soignante engagée et fondatrice de "Mû Médecine", l'école de médecine intégrative. 

Resources: Explore the WOCN® Society Mentor Match Program and sign up as a mentor or mentee Join the WOC Nurse Week 2026 celebrations and events About the Speakers: Derik Alexander, MSN, RN, FNP-BC, CWOCN, CFCN, has been a member of the WOCN Society for over years. He is a WOC Nurse Practitioner at Dignity Health Medical Group and St. Joseph's Hospital & Medical Center in Phoenix, Arizona. He currently serves as President-Elect of the WOCN Society. His educational background includes a Master of Science in Nursing as a Family Nurse Practitioner from the University of Phoenix (2009), as well as completion of the Emory University Wound, Ostomy & Continence Nurse Education program. Ferne Elsass, MSN, RN, CPN, CWON, WOCNF, is an experienced Clinical Instructor with a demonstrated history of working in the hospital and healthcare industry. She is a skilled pediatric registered nurse with certifications in Pediatrics and Wound and Ostomy care, and has a strong clinical focus on pediatric wound and ostomy services. Ferne has presented on pediatric wound care locally, nationally, and internationally and is a published content expert in the field. She has also served on the Mid-Atlantic Chapter WOCN board in multiple roles over a 10-year period and currently supports the board as Past President. Emilee Bartolo, BSN, RN, CWOCN, is a WOC nurse practicing in the outpatient setting at a suburban wound clinic, where she has worked for over 15 years. Prior to this role, she spent 10 years in home health care. She obtained her WOC certification in July 2003. Emilee is actively involved in the WOCN Society through national and chapter volunteer roles. She previously served as Chair of the Membership Engagement Committee, where she helped develop the Mentor Match Program launched in 2025. Vashti Livingston, MS, RN, CWOCN, has been a member of the WOCN Society for over 20 years. She has served as a WOC nurse co-facilitator for an ostomy support group for two decades and has worked for 21 years at Memorial Sloan-Kettering Cancer Center in the Urology Ambulatory Division, primarily supporting urological outpatient clients. She has served two terms as a Director of the WOCN Society and has contributed to numerous committees and projects. Her experience also includes serving as an editor of a peer-reviewed journal and committee member of the International WCET Norma Gill Foundation. Vashti has presented at 11 international conferences on ostomy care and WOC practice, in addition to numerous local and regional presentations across the U.S. She has precepted and mentored numerous WOC nurses over the past 20 years and remains active in community initiatives promoting bladder and colon cancer awareness. She co-facilitates an online bladder cancer support group and volunteers with the United Ostomy Associations of America (UOAA). She has also served as a clinical expert on two ostomy online forums and as a clinical advisor for ostomy products and services for three major companies. She is currently a speaker for Coloplast's ostomy division.   Editing and post-production work for this episode was provided by The Podcast Consultant.

In this episode, we talk with Caroline Chen, MD, a recently matched dermatology resident. Caroline is graduating from Columbia University Vagelos College of Physicians and Surgeons this May and successfully matched into dermatology at Columbia, along with a transitional year at Memorial Sloan Kettering Cancer Center. Listen in as Caroline walks us through her journey to dermatology, how she got involved early on, and why she chose to apply without a research year. We also learn more about her experience with social media and how she balanced her interest in educational content creation with her medical career. We hope you enjoy!If you enjoyed this episode, please share it with other students interested in dermatology!Connect with Caroline: YouTube: https://www.youtube.com/@CarolineChenInstagram: https://www.instagram.com/car.xo.line/Bio Site: https://bio.site/carolinechenhttps://www.tiktok.com/@car.xo.line---DIGA Instagram: @derminterestToday's Host, Cecile: @cecileschreidah---For questions, comments, or future episode suggestions, please reach out to us via email at derminterestpod@gmail.com---District Four by Kevin MacLeodLink: https://incompetech.filmmusic.io/song/3662-district-fourLicense: https://filmmusic.io/standard-license---

In a conversation with CancerNetwork®, Shari Goldfarb, MD spoke about key developments and challenges regarding the treatment of younger populations with breast cancer. Key areas across the field included the rising incidence of disease, including HER2-positive and triple-negative subtypes; expanding opportunities for clinical trial enrollment; and preserving fertility among patients undergoing treatment, among other focuses.Although it's not entirely clear why breast cancer diagnoses are becoming more common in younger groups, Goldfarb noted that a combination of genetic and environmental factors may be driving this increase. Beyond facilitating yearly mammograms among average-risk individuals starting at age 40, she said that knowing one's family history and genetic risk may also inform personalized screening approaches.Goldfarb also described how patients in their 20s to 40s may be underrepresented in breast cancer clinical trials due to enrollment criteria typically requiring postmenopausal status, which may be amended by expanding eligibility to patients who receive medically suppressive therapy. The conversation also touched upon providing supportive care for younger patients with breast cancer, as Goldfarb emphasized prompt fertility consultations following diagnosis for patients who desire to have children as well as other services related to integrative medicine and social work.Additionally, Goldfarb reviewed strategies for mitigating chemotherapy-induced alopecia, highlighting how modalities like scalp cooling may reduce hair loss and improve hair regrowth. In the end, she noted the importance of employing a multi-disciplinary approach to ensure whole-person care and meet the emotional and psychological needs of patients who undergo treatment.“Patients should always advocate for themselves…If something is different in your body, you should make sure to bring it to a doctor's attention,” Goldfarb stated. “[Patients should] make sure they get imaging or a biopsy if they need it. [They should not] wait because early diagnosis helps with finding things at an earlier stage and [yielding] better prognosis.”Goldfarb is an assistant attending physician specializing in breast cancer at Memorial Sloan Kettering Cancer Center.

In this segment of Cancer Registry World, Laurie Kirstein, MD, FACS, a breast surgical oncologist in the Division of Surgical Oncology at Memorial Sloan Kettering Cancer Center and current Chair of the American College of Surgeons Commission on Cancer (CoC), discusses her vision and priorities for the CoC. Drawing on the power of cancer registry data, she highlights the essential role Oncology Data Specialists play in advancing cancer care, quality measurement, and program improvement. Tune in to hear how data-driven insights are shaping the future of oncology.

In this episode of the Eye Believe Podcast, we're joined by Adrián Franco, Ph.D., founder of Broken Not Broke, an initiative dedicated to addressing the often-overlooked financial toxicity of childhood cancer.   After his son was diagnosed with Ewing sarcoma in 2022, Adrián experienced firsthand the overwhelming financial challenges families face during treatment. In response, he created Broken Not Broke to help connect the dots—serving as a centralized resource that links patients, parents, social workers, and caregivers to organizations offering financial assistance for pediatric cancer families across the United States.   In this conversation, Adrián shares: His personal journey as a cancer parent The real impact of financial strain on families How Broken Not Broke functions as a national resource hub Why improving access to financial support is critical for families' long-term well-being   Adrián is also the Executive Director of the Guarini Institute for International Education and Economic Mobility and serves on the Patient and Family Advisory Council for Quality at Memorial Sloan Kettering Cancer Center.   This episode shines a light on an important gap in cancer care—and offers hope, resources, and direction for families who need it most.   Check out Broken Not Broke- https://brokennotbroke.org https://youtube.com/@thebrokennotbrokeinterview?si=4h220ZDNSxME3BT7

In this episode, Rick Peng, Digital Ventures Lead in Memorial Sloan Kettering Cancer Center (MSK) Office of Entrepreneurship & Commercialization & Natalia Summerville, PhD, Director of Decision Intelligence at Memorial Sloan Kettering Cancer Center, discuss how MSK is advancing AI across clinical care and research while building a robust governance model. They share insights on balancing innovation with safety, ensuring accountability, and driving real impact through thoughtful AI deployment and monitoring.

Osteosarcoma Webinar Series: Ali Cihan, PhD, a research scholar at Memorial Sloan Kettering Cancer Center, will discuss his OutSmarting Osteosarcoma funded work on targeting EPHA2 with dual-armored CAR T cells for immunotherapy in pediatric osteosarcoma.Dr. Ali Cihan is a research scholar at Memorial Sloan Kettering Cancer Center, where he focuses on immunotherapy with a particular emphasis on advancing cellular therapies for pediatric solid tumors, including osteosarcoma. He received his Ph.D. from The Rockefeller University, where his research explored how chromosomal abnormalities and transcriptional dysregulation contribute to the development of high-risk pediatric leukemias. Motivated by the urgent need to improve outcomes for children with cancer, especially those facing limited treatment options, Dr. Cihan turned his focus to bridging laboratory discoveries and clinical application. His current work aims to develop immune-based therapeutic strategies that address the unique biological and clinical challenges of pediatric cancers.

In this episode, Rick Peng, Digital Ventures Lead in Memorial Sloan Kettering Cancer Center (MSK) Office of Entrepreneurship & Commercialization & Natalia Summerville, PhD, Director of Decision Intelligence at Memorial Sloan Kettering Cancer Center, discuss how MSK is advancing AI across clinical care and research while building a robust governance model. They share insights on balancing innovation with safety, ensuring accountability, and driving real impact through thoughtful AI deployment and monitoring.

In today's episode, Jae Park, MD, discussed all things CAR T-cell therapy in acute lymphoblastic leukemia (ALL), touching on topics like where this treatment modality fits into the ALL paradigm, how it affects clinical practice, and how to go about selecting between the multiple FDA-approved options. Dr Park is the chief of the Cellular Therapy Service at Memorial Sloan Kettering Cancer Center in New York, New York. In our exclusive interview, Dr Park began with a conversation about the November 2024 FDA approval of obecabtagene autoleucel (obe-cel; Aucatzyl) and the October 2021 FDA approval of brexucabtagene autoleucel (brexu-cel; Tecartus) for patients with ALL. He explained how these CAR T-cell therapies fit into the ALL treatment paradigm for patients who have relapsed disease. After weighing how the safety and efficacy of each therapy stack up against others, Dr Park then discussed analyses that have come out after the obe-cel approval and their effect on obe-cel usage. Dr Park pointed out real-world studies presented at the 2025 ASH Annual Meeting, as well as analyses of the phase 1/2 FELIX trial (NCT04404660), which supported the approval of obe-cel. Finally, Dr Park looked ahead to the future of CAR T-cell therapies for ALL, noted in which settings he believes this class of agents will see the most use, and explained how to make treatment selections between therapies like brexu-cel and obe-cel.  

With the increasing incidence of colorectal cancer in those less than 50 years of age, one must wonder how many patients present with a Stage IV diagnosis. Take a deep dive with us discussing the management of metastatic colorectal cancer by joining our team and guests, Drs. Cathy Eng, Michael D'Angelica, and Nina Sanford.Hosts: - Dr. Janet Alvarez - General Surgery Resident at New York Medical College/Metropolitan Hospital Center- Dr. Wini Zambare – General Surgery Resident at Weill Cornell Medical Center/New York Presbyterian- Dr. Philip Bauer, Assistant Professor of Surgery, Division of Colon and Rectal Surgery, The Ohio State University Wexner Medical Center, Arthur G. James Cancer Hospital-  Dr. J. Joshua Smith MD, PhD, Chair, Department of Colon and Rectal Surgery at MD Anderson Cancer Center Guest Speakers:- Dr. Michael D'Angelica MD, FACS – Hepatopancreatobiliary Surgery, Memorial Sloan Kettering Cancer Center, Enid A. Haupt Chair in Surgery, Vice Chair, Education- Dr. Cathy Eng MD, FACP - Division of Hematology and Oncology, Vanderbilt-Ingram Cancer Center, David H. Johnson Endowed Chair in Surgical and Medical Oncology, Professor of Medicine, Hematology and Oncology, VICC Associate Director for Strategic Relations and Research Partnerships, Executive Director, Young Adult Cancers Program - Dr. Nina Sanford, MD – Radiation Oncology, UT Southwestern Medical Center, Chief of Gastrointestinal Radiation Oncology Service, Associate Professor Learning Objectives:1.     Review the epidemiology, prognosis, and common metastatic patterns of metastatic colorectal cancer (mCRC).2.     Discuss the role of systemic chemotherapy and targeted therapies in the first- and subsequent-line treatment of mCRC, including the impact of molecular biomarkers such as MSI/MMR, RAS, BRAF, and HER2.3.     Evaluate the indications and timing of surgical and locoregional therapies for metastatic colorectal cancer, particularly in patients with liver-limited or oligometastatic disease.4.     Describe the multidisciplinary management of mCRC, including the roles of radiation therapy, systemic therapy sequencing, and palliative interventions to optimize outcomes and quality of life.References:Singh, M., Morris, V. K., Bandey, I. N., Hong, D. S. & Kopetz, S. Advancements in combining targeted therapy and immunotherapy for colorectal cancer. Trends Cancer 10, 598–609 (2024). PubMed Link: https://pubmed.ncbi.nlm.nih.gov/38821852/Napolitano, S. et al. BRAFV600E mutant metastatic colorectal cancer: Current advances in personalized treatment and future perspectives. Cancer Treat. Rev. 134, (2025). PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40009904/Ciardiello, F. et al. Clinical management of metastatic colorectal cancer in the era of precision medicine. CA. Cancer J. Clin. 72, 372–401 (2022). PubMed Link: https://pubmed.ncbi.nlm.nih.gov/35472088/Kim, S. Y. & Kim, T. W. Current challenges in the implementation of precision oncology for the management of metastatic colorectal cancer. ESMO Open 5, e000634 (2020). PubMed Link: https://pubmed.ncbi.nlm.nih.gov/32188714/Biller, L. H. & Schrag, D. Diagnosis and Treatment of Metastatic Colorectal Cancer: A Review. JAMA 325, 669–685 (2021). PubMed Link: https://pubmed.ncbi.nlm.nih.gov/33591350/Smith, J. J. et al. Genomic stratification beyond Ras/B-Raf in colorectal liver metastasis patients treated with hepatic arterial infusion. Cancer Med. 8, 6538–6548 (2019). PubMed Link: https://pubmed.ncbi.nlm.nih.gov/31503397/Saadat, L. V. et al. Hepatic Artery Infusion Chemotherapy Compared to Transarterial Radioembolization For Unresectable Colorectal Liver Metastases. Ann. Surg. 10.1097/SLA.0000000000006851 doi:10.1097/SLA.0000000000006851. PubMed Link: https://pubmed.ncbi.nlm.nih.gov/?term=10.1097/SLA.0000000000006851 (Linked via DOI search as the direct PMID is still indexing)Xiao, A. & Fakih, M. KRAS G12C Inhibitors in the Treatment of Metastatic Colorectal Cancer. Clin. Colorectal Cancer 23, 199–206 (2024). PubMed Link: https://pubmed.ncbi.nlm.nih.gov/38825433/André, T. et al. Pembrolizumab in Microsatellite-Instability–High Advanced Colorectal Cancer. N. Engl. J. Med. 383, 2207–2218 (2020). PubMed Link: https://pubmed.ncbi.nlm.nih.gov/33264544/Morris, V. K. et al. Treatment of Metastatic Colorectal Cancer: ASCO Guideline. J. Clin. Oncol. 41, 678–700 (2023). PubMed Link: https://pubmed.ncbi.nlm.nih.gov/36252154/Xu, Z. et al. Treatments for Stage IV Colon Cancer and Overall Survival. J. Surg. Res. 242, 47–54 (2019). PubMed Link: https://pubmed.ncbi.nlm.nih.gov/31071604/Smith, J. J. & D'Angelica, M. I. Surgical Management of Hepatic Metastases of Colorectal Cancer. Hematol. Oncol. Clin. North Am. 29, 61–84 (2015). PubMed Link: https://pubmed.ncbi.nlm.nih.gov/25475573/Strickler, J. H. et al. Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study. Lancet Oncol. 24, 496–508 (2023). PubMed Link: https://pubmed.ncbi.nlm.nih.gov/37142372/Kruijssen, D. E. W. van der et al. Upfront resection versus no resection of the primary tumor in patients with synchronous metastatic colorectal cancer: the randomized phase III CAIRO4 study conducted by the Dutch Colorectal Cancer Group and the Danish Colorectal Cancer Group. Ann. Oncol. 35, 769–779 (2024). PubMed Link: https://pubmed.ncbi.nlm.nih.gov/38852675/Hitchcock, K. E., Romesser, P. B. & Miller, E. D. Local Therapies in Advanced Colorectal Cancer. Hematol. Oncol. Clin. North Am. 36, 553–567 (2022). PubMed Link: https://pubmed.ncbi.nlm.nih.gov/35562258/Hitchcock, K. E. et al. Alliance for clinical trials in Oncology (Alliance) trial A022101/NRG-GI009: a pragmatic randomized phase III trial evaluating total ablative therapy for patients with limited metastatic colorectal cancer: evaluating radiation, ablation, and surgery (ERASur). BMC Cancer 24, 201 (2024). PubMed Link: https://pubmed.ncbi.nlm.nih.gov/38350888/Adam, R. et al. Liver transplantation plus chemotherapy versus chemotherapy alone in patients with permanently unresectable colorectal liver metastases (TransMet): results from a multicentre, open-label, prospective, randomised controlled trial. The Lancet 404, 1107–1118 (2024). PubMed Link: https://pubmed.ncbi.nlm.nih.gov/39306468/Elez, E. et al. Encorafenib, Cetuximab, and mFOLFOX6 in BRAF-Mutated Colorectal Cancer. N. Engl. J. Med. 392, 2425–2437 (2025). PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40444708/***Fellowship Application Link: https://forms.gle/QSUrR2GWHDZ1MmWC6Please visit https://behindtheknife.org to access other high-yield surgical education podcasts, videos and more.  If you liked this episode, check out our recent episodes here: https://behindtheknife.org/listenBehind the Knife Premium:General Surgery Oral Board Review Course: https://behindtheknife.org/premium/general-surgery-oral-board-reviewTrauma Surgery Video Atlas: https://behindtheknife.org/premium/trauma-surgery-video-atlasDominate Surgery: A High-Yield Guide to Your Surgery Clerkship: https://behindtheknife.org/premium/dominate-surgery-a-high-yield-guide-to-your-surgery-clerkshipDominate Surgery for APPs: A High-Yield Guide to Your Surgery Rotation: https://behindtheknife.org/premium/dominate-surgery-for-apps-a-high-yield-guide-to-your-surgery-rotationVascular Surgery Oral Board Review Course: https://behindtheknife.org/premium/vascular-surgery-oral-board-audio-reviewColorectal Surgery Oral Board Review Course: https://behindtheknife.org/premium/colorectal-surgery-oral-board-audio-reviewSurgical Oncology Oral Board Review Course: https://behindtheknife.org/premium/surgical-oncology-oral-board-audio-reviewCardiothoracic Oral Board Review Course: https://behindtheknife.org/premium/cardiothoracic-surgery-oral-board-audio-reviewDownload our App:Apple App Store: https://apps.apple.com/us/app/behind-the-knife/id1672420049Android/Google Play: https://play.google.com/store/apps/details?id=com.btk.app&hl=en_US

In today's episode, we welcomed Saad Z. Usmani, MD, MBA, FACP, FASCO, to discuss the significance of the January 2026 FDA approval of daratumumab and hyaluronidase-fihj (Darzalex Faspro) in combination with bortezomib (Velcade), lenalidomide (Revlimid), and dexamethasone (VRd) for the treatment of adult patients with newly diagnosed multiple myeloma who are not eligible for autologous stem cell transplant (ASCT).Usmani is chief of Myeloma Service at Memorial Sloan Kettering Cancer Center in New York, New York, and the recipient of the 2025 Giants of Cancer Care award for multiple myeloma.In the exclusive interview, Dr Usmani explained the clinical implications of the regulatory decision that expanded the indication for daratumumab plus VRd to the transplant-ineligible setting, detailed the pivotal data from the phase 3 CEPHEUS trial (NCT03652064) that supported the approval, and provided context for treatment strategies with this regimen in clinical practice.

Welcome to the Oncology Brothers podcast! In this episode we continue our series on breast cancer treatment algorithms, focusing specifically on triple negative breast cancer (TNBC). We welcomed Dr. Tiffany Traina, a breast medical oncologist from the Memorial Sloan Kettering Cancer Center, to discuss the latest advancements in the management of TNBC. We dived deep into the treatment algorithm for early-stage disease, including the criteria for adjuvant chemotherapy, the use of neoadjuvant therapies like KEYNOTE-522, and the importance of balancing risk and benefit in treatment decisions. Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ Key topics covered in this episode included: * Criteria for adjuvant chemotherapy in early-stage TNBC * The role of pembrolizumab in neoadjuvant and adjuvant settings * Management of residual disease with capecitabine and olaparib * Insights into the latest clinical trials, including ASCENT-03, ASCENT-04, and TROPION-Breast02 * Side effect management strategies for new therapies Don't forget to subscribe for more episodes in our breast cancer series, and feel free to send us your questions and cases! Listen now and stay informed on the evolving landscape of triple negative breast cancer treatment! #TripleNegativeBreastCancer, #TNBC, #Pembrolizumab, #ADC, #OncologyBrothers

For patient referrals: call 480-256-6444Can ultrasound liquefy tumors? In this episode of Beyond the Rounds, we explore histotripsy — a novel, non-thermal ultrasound therapy that can destroy tumors without surgery, heat, or radiation. Dr. Nolan Fisher sits down with surgical oncologist Dr. Michael Choti, Chief of Surgery at Banner MD Anderson Cancer Center, to discuss how this emerging technology may change the way liver tumors are treated.Using focused ultrasound energy to create microscopic cavitation bubbles, histotripsy mechanically breaks down tumor tissue while sparing critical structures like blood vessels and bile ducts. The result: precise tumor destruction in locations that may be difficult or impossible to treat with traditional surgery or thermal ablation.This episode explores how histotripsy works, where it fits in today's treatment landscape, and why clinicians should remain both excited and cautious as the technology evolves.This episode is designed for physicians, advanced practice providers, and clinicians who want a practical understanding of emerging technologies in surgical oncology and liver tumor management.What We Cover• What histotripsy is and how cavitation-based ultrasound destroys tumors• Why histotripsy differs from thermal ablation techniques• The “heat sink effect” and why tumors near blood vessels are difficult to treat• How histotripsy may expand treatment options for liver tumors• Using histotripsy as a bridge to liver transplant• The potential immune effects of tumor liquefaction (abscopal effect)• When histotripsy is appropriate — and when it's not• Current FDA approvals and ongoing research• Why careful patient selection and multidisciplinary evaluation matterKey Topics for CliniciansLiver tumorsColorectal liver metastasesHepatocellular carcinoma (HCC)Liver transplant bridging therapyImage-guided tumor ablationHistotripsy technologySurgical oncology innovationMultidisciplinary cancer careAbout Our GuestDr. Michael Choti is Chief of Surgery at Banner MD Anderson Cancer Center and a nationally recognized surgical oncologist specializing in gastrointestinal and hepatobiliary cancers. His career has focused on liver tumors, colorectal cancer metastases, and advancing surgical and minimally invasive treatments for complex cancers. He previously served as Chair of the Department of Surgery at UT Southwestern and trained at Yale, the University of Pennsylvania, and Memorial Sloan Kettering Cancer Center.How to Refer a PatientIf you believe a patient may benefit from evaluation at Banner MD Anderson Cancer Center:Banner Health providers: Use Cerner's Ambulatory Referral Management (ARM) tool.Community providers:Fax referrals to 480-256-4607or call 480-256-6444 to schedule a patient for evaluation.DisclaimerThis podcast is intended for educational purposes only and is designed for a clinical audience. Any patient scenarios discussed are modified and de-identified to protect privacy. No protected health information (PHI) is disclosed. The information presented should not replace independent medical judgment or individualized patient care decisions.Subscribe to Beyond the Rounds for physician-focused conversations on clinical innovation, specialty collaboration, and evolving standards of care.

Gabrielle Rizzuto from Memorial Sloan Kettering Cancer Center discusses her work on the curious immunology of pregnancy and how a woman tolerates a genetically different baby but quickly rejects a mismatched organ donation. Host: Cindy Leifer Guest: Gabrielle Rizzuto Subscribe (free): Apple Podcasts, RSS, email Become a patron of Immune! Links for this episode MicrobeTV Discord Server Rizzuto lab at MSKCC Tolerance at the fetal-maternal interface (Nature, 2022) The paradox of fetal-maternal tolerance (J Exp Med, 2022) Spatially resolved timeline of fetal-maternal interface (Nature, 2023) Time stamps by Jolene Ramsey. Thanks! Music by Tatami. Logo image by Blausen Medical Send your immunology questions and comments to immune@microbe.tv Information on this podcast should not be construed as medical advice.

In this episode, Jeff Flaks, CEO of Hartford HealthCare, shares how the organization is leveraging AI, virtual care, remote monitoring, and a new partnership with Memorial Sloan Kettering Cancer Center to expand access, improve quality, and make care more human and affordable. He outlines a bold vision focused on being the best at getting better while navigating policy and operational headwinds.

Osteosarcoma Webinar Series: Corey Weistuch, PhD, an Assistant Attending Physicist in the Service for Predictive Informatics within the Department of Medical Physics at Memorial Sloan Kettering Cancer Center, will discuss his OutSmarting Osteosarcoma funded work on implementing personalized, adaptive therapies in osteosarcoma.Corey Weistuch, PhD, is an Assistant Attending Physicist in the Service for Predictive Informatics within the Department of Medical Physics at Memorial Sloan Kettering Cancer Center. His work is focused on developing mathematical models to understand cancer development, progression, and metastasis by integrating multimodal data. Central to this approach is the recognition that tumors occupy a finite spectrum of functional states, each characterized by distinct treatment sensitivities and metastatic tendencies that evolve over time and in response to therapy. His research centers on two primary objectives: 1) developing innovative mathematical tools to identify cancer phenotype drivers, and 2) precision modeling of cancer evolution and site-specific metastatic dissemination. By leveraging his interdisciplinary training in mathematics and biology, he collaborates closely with experimental biologists and clinicians to ensure that his computational predictions are effectively translated into tangible clinical applications and trials.The Weistuch Lab's work aims to validate targeted drug candidates for osteosarcoma (OS) using patient-derived xenograft (PDX) models, leveraging a newly developed atlas of OS transcriptional states, called archetypes, to guide personalized, adaptive treatment strategies. By testing archetype-specific therapies in different disease phases, they establish a foundation for precision-based clinical trials, ultimately with the goal of improving outcomes for patients with advanced or refractory OS.

Every other week I'm republishing one of my most popular or impactful episodes from my backlog of over 450 episodes. This week I'm highlighting Episode 279, which is all about bone marrow transplants. ___________________ *For an excellent summary of the neutropenic diet, ⁠check out this resource from Memorial Sloan Kettering Cancer Center⁠. * Interested in saving a life? Register with ⁠⁠Be The Match⁠⁠. ⁠Full Transcript⁠ - Read the article and view references ⁠FREE CLASS⁠ - If all you've heard are nursing school horror stories, then you need this class! Join me in this on-demand session where I dispel all those nursing school myths and show you that YES...you can thrive in nursing school without it taking over your life! ⁠LATTE Method Template⁠ - Download the free LATTE Method Template so you can streamline how you study and focus on what a nurse needs to know. ⁠Med Surg Solution⁠ - Are you looking for a more effective way to learn Med Surg? Enroll in Med Surg Solution and get lessons on 57 key topics and out-of-this-world study guides.

This week I'm reading from Bruce Rapuano's book 'Dominion Lost: A Scientist's Own Alien Encounters'.This bombshell nonfiction book, recently discussed by the author with George Knapp on Coast to Coast AM, is the only first-person account to date of UFO alien abductions authored by a mainstream American scientist. The author, who has multiple degrees in neuroscience, goes on the record regarding his incredible and fascinating experiences with UFO close encounters, including a very close encounter during which he was abducted from a group of eight other witnesses, interactions with alien beings and an unexplained nasal implant of specific structure all of which were recalled without regressive hypnosis. Also riveting are the author's experiences with short humanoid beings that are described in captivating detail to reveal all the ways that aliens control human behavior during the abduction process.Even more amazing is the fact that this book is the first to explain : how the implants that are frequently reported by abductees work to analyze and influence the activity of the human brain. Exactly how the “grey aliens” were genetically reengineered from our early hominin ancestors. Precisely how the UFO propulsion system creates gravitational wave energy.At the same time, relying on his professional background, insight from his personal abduction experiences and numerous cited scientific articles from peer-reviewed journals, the author demonstrates that the ultrasophisticated technical capabilities exhibited by the alien visitors to our planet are more than plausible. They represent a logical extrapolation of current human theoretical and applied science.Moreover, the powerful evidence of such technology which has existed for more than 60 years, especially with respect to incredibly advanced propulsion systems for interstellar space travel and implanted devices that are likely instruments of mind control, proves that the aliens are here. Potentially breakthrough scientific innovations underlying these highly advanced alien capabilities are revealed and clearly explained, making the book a de facto whistleblower report on the subject of UFO's and alien abduction. More importantly, this book is a wake-up call to our species to finally accept the reality that we are now sharing our world with technologically superior alien beings. This new reality must be addressed immediately.BioBruce Rapuano a B.A. degree from the University of Pennsylvania where he majored in Neurobiology and minored in Psychology, a Ph.D. in Neuropharmacology from the University of Connecticut and a J.D. from New York Law School. Dr. Rapuano has conducted independent biomedical research as a cell biologist at internationally recognized medical institutions including the Memorial Sloan-Kettering Cancer Center and the Hospital for Special Surgery, both located in New York City. He has authored or coauthored thirty scientific articles in peer-reviewed medical journals. He has published articles on topics such as the role of membrane phospholipids in nerve function, the skeletal effects of cancer metastases, metabolic bone diseases and the coordinate surface electrical and biological properties of titanium alloy implant materials. Dr. Rapuano has also worked concurrently as a medical research scientist and Associate Radiation Safety Officer at the Hospital for Special Surgery.Amazon link https://www.amazon.com/dp/B0CQFKDMMW https://www.pastliveshypnosis.co.uk/https://www.patreon.com/alienufopodcastMy book 'Verified Near Death Exeriences' https://www.amazon.com/dp/B0DXKRGDFP Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

This week I'm talking to Bruce Rapuano about his book 'Dominion Lost: A Scientist's Own Alien Encounters'.This bombshell nonfiction book, recently discussed by the author with George Knapp on Coast to Coast AM, is the only first-person account to date of UFO alien abductions authored by a mainstream American scientist. The author, who has multiple degrees in neuroscience, goes on the record regarding his incredible and fascinating experiences with UFO close encounters, including a very close encounter during which he was abducted from a group of eight other witnesses, interactions with alien beings and an unexplained nasal implant of specific structure all of which were recalled without regressive hypnosis. Also riveting are the author's experiences with short humanoid beings that are described in captivating detail to reveal all the ways that aliens control human behavior during the abduction process.Even more amazing is the fact that this book is the first to explain : how the implants that are frequently reported by abductees work to analyze and influence the activity of the human brain. Exactly how the “grey aliens” were genetically reengineered from our early hominin ancestors. Precisely how the UFO propulsion system creates gravitational wave energy.At the same time, relying on his professional background, insight from his personal abduction experiences and numerous cited scientific articles from peer-reviewed journals, the author demonstrates that the ultrasophisticated technical capabilities exhibited by the alien visitors to our planet are more than plausible. They represent a logical extrapolation of current human theoretical and applied science.Moreover, the powerful evidence of such technology which has existed for more than 60 years, especially with respect to incredibly advanced propulsion systems for interstellar space travel and implanted devices that are likely instruments of mind control, proves that the aliens are here. Potentially breakthrough scientific innovations underlying these highly advanced alien capabilities are revealed and clearly explained, making the book a de facto whistleblower report on the subject of UFO's and alien abduction. More importantly, this book is a wake-up call to our species to finally accept the reality that we are now sharing our world with technologically superior alien beings. This new reality must be addressed immediately.BioBruce Rapuano a B.A. degree from the University of Pennsylvania where he majored in Neurobiology and minored in Psychology, a Ph.D. in Neuropharmacology from the University of Connecticut and a J.D. from New York Law School. Dr. Rapuano has conducted independent biomedical research as a cell biologist at internationally recognized medical institutions including the Memorial Sloan-Kettering Cancer Center and the Hospital for Special Surgery, both located in New York City. He has authored or coauthored thirty scientific articles in peer-reviewed medical journals. He has published articles on topics such as the role of membrane phospholipids in nerve function, the skeletal effects of cancer metastases, metabolic bone diseases and the coordinate surface electrical and biological properties of titanium alloy implant materials. Dr. Rapuano has also worked concurrently as a medical research scientist and Associate Radiation Safety Officer at the Hospital for Special Surgery.Amazon link https://www.amazon.com/dp/B0CQFKDMMW https://www.pastliveshypnosis.co.uk/https://www.patreon.com/alienufopodcastMy book 'Verified Near Death Exeriences' https://www.amazon.com/dp/B0DXKRGDFP Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode of It Takes Balls, Dr. Darren Feldman, a genitourinary medical oncologist at Memorial Sloan Kettering Cancer Center, provides a deep, evidence-based conversation on testicular cancer treatment, chemotherapy decision-making, and long-term survivorship. Dr. Feldman breaks down how cisplatin transformed testicular cancer from a fatal disease into one of the most curable solid tumors, even in cases of metastatic disease.The discussion explores the differences between BEP, EP, VIP, and TIP chemotherapy regimens, including when and why each is used, how doctors balance cure rates with toxicity, and why lung health, kidney function, age, and patient goals matter when choosing treatment. Dr. Feldman also explains why cisplatin remains superior to carboplatin in advanced germ cell tumors, when surveillance is preferred over treatment in stage 1 disease, and how overtreatment can carry long-term risks.Later in the episode, Dr. Feldman addresses common patient concerns around recurrence risk, radiation vs surveillance, retroperitoneal lymph node dissection (RPLND), testosterone changes after chemotherapy, and misinformation surrounding alternative therapies.Provide your feedback on the podcast:https://www.testicularcancerawarenessfoundation.org/itbsurveyHave a question for a future expert guest? Submit here:https://www.testicularcancerawarenessfoundation.org/it-takes-balls-question-submissionWant to be a guest? Apply here:https://www.testicularcancerawarenessfoundation.org/it-takes-balls-submissionsFollow Testicular Cancer Awareness Foundation:⁠https://www.testescancer.orghttps://www.twitter.com/testescancer⁠⁠https://www.instagram.com/testescancerhttps://www.facebook.com/tca.orgDr. Feldman:https://www.mskcc.org/cancer-care/doctors/darren-feldmanFollow Steven Crocker:https://www.instagram.com/stevencrockerhttps://www.facebook.com/steven.crocker2Theme song: No Time Like Now - Tom Willner www.tomwillner.com

This episode features Selwyn M. Vickers, MD, FACS, a pancreatic cancer surgeon and president and CEO of Memorial Sloan Kettering Cancer Center in New York. During the American College of Surgeons Commission on Cancer Oncology Lecture at Clinical Congress 2025, Dr. Vickers discussed a transformative era in cancer care, where scientific breakthroughs are reshaping cancer therapeutics and redefining the role of surgeons. Talk about the podcast on social media using the hashtag #HouseofSurgery

Dr. Evan Noch interviews Dr. Lisa DeAngelis about her career in neuro-oncology, role as Chair of Neurology and Physician-in-Chief at Memorial Sloan Kettering Cancer Center, and advice for trainees entering the field.

In today's episode, recorded in recognition of World Cancer Day, we spoke with Deb Schrag, MD, MPH. Dr Schrag is a medical oncologist at Memorial Sloan Kettering Cancer Center and a nationally recognized leader in cancer outcomes research, health equity, and evidence-based care delivery.In our exclusive interview, Dr Schrag discussed the importance of standardizing high-quality cancer care, addressing inequities in access and outcomes, and how the oncology community can work together to ensure that advances in cancer treatment translate into meaningful benefits for all patients. 

In today's episode, the discussion features Komal Jhaveri, MD, FACP, a breast medical oncologist at Memorial Sloan Kettering Cancer Center, who reviewed the evolving role of TROP2-directed antibody–drug conjugates (ADCs) in the management of hormone receptor (HR)–positive, HER2-negative metastatic breast cancer. She drew on findings from the phase 3 ASCENT-07 trial (NCT05840211), which evaluated sacituzumab govitecan-hziy (Trodelvy) in the first-line setting following endocrine therapy for patients with HR-positive, HER2-negative metastatic breast cancer.In this exclusive interview, Dr Jhaveri discussed the rationale for evaluating sacituzumab govitecan earlier in the treatment paradigm, summarized key efficacy outcomes from ASCENT-07, and contextualized why the trial did not meet its primary progression-free survival end point. She also highlighted how disease biology and patient selection may influence outcomes when ADCs are moved into earlier lines of therapy, and outlined practical considerations for toxicity management and future trial design as the TROP2 ADC landscape continues to evolve.asts, Spotify, and many of your other favorite podcast platforms,* so you get a notification every time a new episode is posted. While you are there, please take a moment to rate us!

Dr Angela DeMichele from the Abramson Cancer Center in Philadelphia, Pennsylvania, Dr Komal Jhaveri from Memorial Sloan Kettering Cancer Center in New York, New York, Dr Erica Mayer from Dana-Farber Cancer Institute in Boston, Massachusetts, Dr Hope S Rugo from City of Hope Comprehensive Cancer Center in Duarte, California, and Dr Seth Wander from Massachusetts General Hospital in Boston discuss real-world cases and recent clinical data surrounding the management of HR-positive breast cancer.CME information and select publications here.

Picture this: a patient with early-stage breast cancer is sitting in front of you in the clinic. You are about to offer your expert management plan. The age-old question arises—should you really perform a sentinel lymph node biopsy, or could omission actually help this patient more? Today, we're tackling one of the hottest debates in modern breast cancer care.Should we rethink sentinel lymph node biopsy for select patients, and can skipping it actually improve quality of life without sacrificing cancer control? The stakes couldn't be higher—balancing accurate cancer staging and minimizing harm is the name of the game. Together, we're breaking down the latest evidence from the SOUND and INSEMA trials. What do these landmark studies mean for your patients, your practice, and the future of axillary management? Ready for a journal review that might just change your next consult? Hosts:- Rashmi Kumar, MD, PhDResident, University of Michigan General Surgery Residency ProgramTwitter/X: @RashmiJKumar- Melissa Pilewskie, MDAttending Breast Surgical Oncologist, Co-Director of the Weiser Family Center for Breast Cancer, Michigan Medicine Twitter/X: @MPilewskie- Stephanie Downs-Canner, MDAttending Breast Surgical Oncologist & Physician-Scientist, Memorial Sloan Kettering Cancer Center, Program Director of the Breast Surgical Oncology Fellowship Training Program Twitter/X: @SDownsCannerLearning Objectives:- Understand when and for whom it is safe and beneficial to omit sentinel lymph node biopsy (SLNB) in early-stage breast cancer patients.- Identify the risks associated with foregoing SLNB, including loss of nodal staging, and analyze how this impacts treatment selection and prognosis.- Review key findings from the SOUND and INSEMA trials and their influence on axillary management.- Discuss implications for adjuvant therapy, genomic profiling, and multidisciplinary clinical practice.- Recognize which patient populations should still receive SLNB, and the importance of individualized, multidisciplinary decision-making.References:- Gentilini OD, Botteri E, Sangalli C, et al. Sentinel Lymph Node Biopsy vs No Axillary Surgery in Patients With Small Breast Cancer and Negative Results on Ultrasonography of Axillary Lymph Nodes: The SOUND Randomized Clinical Trial. JAMA Oncol. 2023;9(11):1557–1564. doi:10.1001/jamaoncol.2023.3759 https://pubmed.ncbi.nlm.nih.gov/37733364/- Reimer T, Stachs A, Veselinovic K, et al. Axillary surgery in breast cancer – primary results of the INSEMA trial. N Eng J Med. 2024. doi:10.1056/NEJMoa2412063.https://pubmed.ncbi.nlm.nih.gov/39665649/- Sparano JA, Gray RJ, Makower DF, Albain KS, Saphner TJ, Badve SS, Wagner LI, Kaklamani VG, Keane MM, Gomez HL, Reddy PS, Goggins TF, Mayer IA, Toppmeyer DL, Brufsky AM, Goetz MP, Berenberg JL, Mahalcioiu C, Desbiens C, Hayes DF, Dees EC, Geyer CE Jr, Olson JA Jr, Wood WC, Lively T, Paik S, Ellis MJ, Abrams J, Sledge GW Jr. Clinical Outcomes in Early Breast Cancer With a High 21-Gene Recurrence Score of 26 to 100 Assigned to Adjuvant Chemotherapy Plus Endocrine Therapy: A Secondary Analysis of the TAILORx Randomized Clinical Trial. JAMA Oncol. 2020 Mar 1;6(3):367-374. doi: 10.1001/jamaoncol.2019.4794. PMID: 31566680; PMCID: PMC6777230. https://pubmed.ncbi.nlm.nih.gov/31566680/- Slamon DJ, Fasching PA, Hurvitz S, Chia S, Crown J, Martín M, Barrios CH, Bardia A, Im SA, Yardley DA, Untch M, Huang CS, Stroyakovskiy D, Xu B, Moroose RL, Loi S, Visco F, Bee-Munteanu V, Afenjar K, Fresco R, Taran T, Chakravartty A, Zarate JP, Lteif A, Hortobagyi GN. Rationale and trial design of NATALEE: a Phase III trial of adjuvant ribociclib + endocrine therapy versus endocrine therapy alone in patients with HR+/HER2- early breast cancer. Ther Adv Med Oncol. 2023 May 29;15:17588359231178125. doi: 10.1177/17588359231178125. Erratum in: Ther Adv Med Oncol. 2023 Sep 29;15:17588359231201818. doi: 10.1177/17588359231201818. PMID: 37275963; PMCID: PMC10233570. https://pubmed.ncbi.nlm.nih.gov/37275963/Sponsor Disclosure: Visit goremedical.com/btkpod to learn more about GORE® SYNECOR Biomaterial, including supporting references and disclaimers for the presented content. Refer to Instructions for Use at eifu.goremedical.com for a complete description of all applicable indications, warnings, precautions and contraindications for the markets where this product is available. Rx only Please visit https://behindtheknife.org to access other high-yield surgical education podcasts, videos and more.  If you liked this episode, check out our recent episodes here: https://behindtheknife.org/listenBehind the Knife Premium:General Surgery Oral Board Review Course: https://behindtheknife.org/premium/general-surgery-oral-board-reviewTrauma Surgery Video Atlas: https://behindtheknife.org/premium/trauma-surgery-video-atlasDominate Surgery: A High-Yield Guide to Your Surgery Clerkship: https://behindtheknife.org/premium/dominate-surgery-a-high-yield-guide-to-your-surgery-clerkshipDominate Surgery for APPs: A High-Yield Guide to Your Surgery Rotation: https://behindtheknife.org/premium/dominate-surgery-for-apps-a-high-yield-guide-to-your-surgery-rotationVascular Surgery Oral Board Review Course: https://behindtheknife.org/premium/vascular-surgery-oral-board-audio-reviewColorectal Surgery Oral Board Review Course: https://behindtheknife.org/premium/colorectal-surgery-oral-board-audio-reviewSurgical Oncology Oral Board Review Course: https://behindtheknife.org/premium/surgical-oncology-oral-board-audio-reviewCardiothoracic Oral Board Review Course: https://behindtheknife.org/premium/cardiothoracic-surgery-oral-board-audio-reviewDownload our App:Apple App Store: https://apps.apple.com/us/app/behind-the-knife/id1672420049Android/Google Play: https://play.google.com/store/apps/details?id=com.btk.app&hl=en_US

In today's episode, the discussion features Lorenzo Falchi, MD, a medical oncologist/hematologist and assistant attending physician in the Lymphoma Service at Memorial Sloan Kettering Cancer Center in New York, New York, who provided clinical and regulatory perspectives on the FDA approval of epcoritamab-bysp (Epkinly) in combination with rituximab (Rituxan) and lenalidomide (Revlimid) for relapsed/refractory follicular lymphoma after at least 2 prior lines of therapy. The approval was supported by primary results from the randomized phase 3 EPCORE FL-1 trial (NCT05409066).In this exclusive interview, Dr Falchi discussed why this approval is clinically meaningful—establishing a chemotherapy-free triplet that significantly improves outcomes over the long-standing rituximab/lenalidomide backbone in the second-line setting and beyond—and reviewed practical considerations that inform real-world uptake of the regimen, including outpatient administration feasibility and mitigation of bispecific antibody–associated toxicities, such as cytokine release syndrome. He also placed EPCORE FL-1 in the broader epcoritamab development program, referencing supportive experience with the phase 1/2 EPCORE NHL-2 trial (NCT04663347) and ongoing efforts to move bispecific antibody–based regimens earlier in the treatment paradigm through the phase 3 EPCORE FL-2 trial (NCT06191744).any of your other favorite podcast platforms,* so you get a notification every time a new episode is posted. While you are there, please take a moment to rate us!

In this episode of Health Matters, host Courtney Allison is joined by Dr. Rekha Kumar, endocrinologist and primary care physician at NewYork-Presbyterian and Weill Cornell Medicine, to unpack the science behind aging well. They discuss biohacking, longevity, and health span, separating evidence-based strategies from social media hype and exploring what truly helps us age well.What You'll Learn in This EpisodeWhat “biohacking” really means● How biohacking ranges from simple lifestyle optimization to high-tech, experimental interventions● The difference between lifespan (how long you live) and health span (how long you live well)The Longevity Pyramid● Why the foundation of healthy aging is built on:SleepMovement and strength trainingNutritionStress managementSocial connection● How advanced tools and supplements sit at the top—and why they should never replace the basicsWearables and Tracking● How devices like smartwatches, glucose monitors, and fitness trackers can support behavior change● When tracking becomes counterproductive or stressfulPeptides and “Anti-Aging” Supplements● What's proven (e.g., metformin, GLP-1 receptor agonists)● What's still experimental or under-studied (BPC-157, sermorelin, NAD boosters)Nootropics and Cognitive Enhancers● Everyday nootropics like caffeine● The role of L-theanine for “calm focus”● Myths around perfectly timed caffeine and cortisol rhythmsNutrigenomics and Personalized Nutrition● How genes can influence responses to foods (e.g., lactose intolerance, APOE and saturated fat)● Why many direct-to-consumer genetic tests may overpromiseThe Gut Microbiome● The role of Akkermansia muciniphila in metabolic health● How medications like metformin and GLP-1s may positively shift gut bacteria● What's still unknown about probiotic supplementationGenetic and Biomarker Testing● The difference between actionable medical insights and “information overload”● Why results of unknown significance can cause unnecessary anxietyThe Big Takeaways● There are no true shortcuts to longevity● Sustainable habits beat quick fixes● Our biology is built for rhythms, not constant optimizationFeatured ExpertAbout Rekha B. Kumar, M.D., M.S.Dr. Rekha B. Kumar is an attending endocrinologist at NewYork-Presbyterian/Weill Cornell Medical Center and an associate professor of Clinical Medicine at Weill Cornell Medicine. She specializes in adult primary care and endocrinology and has academic expertise in the diagnosis and treatment of various endocrine disorders, including obesity/weight management, type 2 diabetes, polycystic ovarian syndrome (PCOS), thyroid disorders, as well as metabolic bone disease.Dr. Kumar completed her undergraduate studies at Duke University and received her masters degree in Physiology from Georgetown University. She received her M.D. from New York Medical College and completed her residency training in Internal Medicine at NewYork-Presbyterian/Weill Cornell Medical Center. Dr. Kumar obtained her clinical fellowship in the combined Diabetes, Endocrinology, and Metabolism program at the NewYork-Presbyterian/Weill Cornell Medical Center and the Memorial Sloan Kettering Cancer Center. Dr. Kumar is Board Certified in Internal Medicine, Endocrinology, Diabetes, & Metabolism, and Obesity Medicine.Coming Up NextIn the next episode of Health Matters, we'll explore brain health and the short- and long-term effects of alcohol on the brain with Dr. Hugh Cahill. Subscribe and follow Health Matters on Apple Podcasts, Spotify, or wherever you listen to stay up to date with expert-driven conversations on living well at every stage of life.About Health MattersHealth Matters is your bi-weekly dose of health and wellness information, from the leading experts. Join host Courtney Allison to get news you can use in your own life. New episodes drop each Wednesday.If you are looking for practical health tips and trustworthy information from world-class doctors and medical experts you will enjoy listening to Health Matters. Health Matters was created to share stories of science, care, and wellness that are happening every day at NewYork-Presbyterian, one of the nation's most comprehensive, integrated academic healthcare systems. In keeping with NewYork-Presbyterian's long legacy of medical breakthroughs and innovation, Health Matters features the latest news, insights, and health tips from our trusted experts; inspiring first-hand accounts from patients and caregivers; and updates on the latest research and innovations in patient care, all in collaboration with our renowned medical schools, Columbia and Weill Cornell Medicine.To learn more visit: https://healthmatters.nyp.org

Prof Claire Harrison from Guy's and St Thomas' NHS Foundation Trust in London, Dr Andrew T Kuykendall from Moffitt Cancer Center, Dr Stephen T Oh from the Washington University School of Medicine, Dr Jeanne Palmer from the Mayo Clinic School of Medicine and Dr Raajit K Rampal from Memorial Sloan Kettering Cancer Center discuss recent updates on available and novel treatment strategies for myelofibrosis and systemic mastocytosis.CME information and select publications here.

Bree Groff is a workplace culture expert and author of Today Was Fun: A Book About Work (Seriously). She has spent her career guiding executives at companies such as Microsoft, Google, Pfizer, Calvin Klein, Point32Health, and Memorial Sloan Kettering Cancer Center through periods of complex change. She is a Senior Advisor to the global consultancy SYPartners, previously served as the CEO of NOBL Collective, and she holds an MS in Learning and Organizational Change from Northwestern University. Bree lives in New York City with her husband and daughter.Link to claim CME credit: https://www.surveymonkey.com/r/3DXCFW3CME credit is available for up to 3 years after the stated release dateContact CEOD@bmhcc.org if you have any questions about claiming credit.

Dr Harry Paul Erba from the Duke Cancer Institute, Dr Amir Fathi from Massachusetts General Hospital, Dr Tara L Lin from The University of Kansas Medical Center, Dr Alexander Perl from the University of Pennsylvania's Abramson Cancer Center and Dr Eytan M Stein from Memorial Sloan Kettering Cancer Center discuss recent data surrounding the management of AML and their perspectives on clinical application.CME information and select publications here.

In this episode, I interview Dr. Shana Burstein, a second-year pediatric hematology-oncology fellow at Children's Healthcare of Atlanta. She received her MD from Albert Einstein College of Medicine in 2021, followed by a residency in Pediatrics at the Children's Hospital at Montefiore. Her current research interest is identifying novel genomic variants associated with pediatric cancer predisposition syndromes. During this conversation, Dr. Burstein shares the challenges and life lessons she learned along the way to becoming a physician. Further, she tells us about the incredible research she has performed from her work with calcium ion channels at Memorial Sloan Kettering Cancer Center to the computational biology work she is spearheading at Emory University. Lastly, we close the interview with Dr. Burstein sharing valuable advice for those aspiring to have a successful and healthy career in medicine. 

Head and neck cancer is the seventh most common cancer worldwide and is commonly associated with tobacco and alcohol use, or human papillomavirus (HPV) infection. Author Lara Dunn, MD, of Memorial Sloan Kettering Cancer Center joins JAMA Associate Editor Margaret Wheeler, MD, to discuss the epidemiology, risk factors, diagnosis, treatment, and prognosis of head and neck cancer. Related Content: Head and Neck Cancer

"I'll go back to the backpack analogy. When your kids come home with a backpack, all of a sudden their homework is not on the desk where it's supposed to be. It's in the kitchen; it kind of spreads all over the place, but it's still in the house. When we give antibody–drug conjugates (ADCs), the chemotherapy does go in, but then it can kind of permeate out of the cell membrane and something right next to it—another cancer cell that might not look exactly like the cancer cell that the chemotherapy was delivered into—is affected and the chemotherapy goes over to that cancer cell and kills it," ONS member Marisha Pasteris, OCN®, office practice nurse in the breast medicine service at Memorial Sloan Kettering Cancer Center in New York, NY, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about ADCs in metastatic breast cancer. Music Credit: "Fireflies and Stardust" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  This podcast is sponsored by Gilead and is not eligible for NCPD contact hours. ONS is solely responsible for the criteria, objectives, content, quality, and scientific integrity of its programs and publications.  Episode Notes  This episode is not eligible for NCPD. ONS Podcast™ episodes: Episode 391: Pharmacology 101: Antibody–Drug Conjugates Episode 378: Considerations for Adolescent and Young Adult Patients With Metastatic Breast Cancer Episode 368: Best Practices for Challenging Patient Conversations in Metastatic Breast Cancer Episode 350: Breast Cancer Treatment Considerations for Nurses Episode 303: Cancer Symptom Management Basics: Ocular Toxicities ONS Voice articles: An Oncology Nurse's Guide to Cancer-Related Ocular Toxicities Black Patients With Metastatic Breast Cancer Are Less Informed About Their Clinical Trial Options Communication Case Study: Talking to Patients About Progressive Metastatic Breast Cancer What Is HER2-Low Breast Cancer? ONS Voice drug reference sheets: Belantamab mafodotin-blmf Datopotamab deruxtecan-dlnk Enfortumab vedotin-ejfv Fam-trastuzumab deruxtecan-nxki ONS books: Chemotherapy and Immunotherapy Guidelines and Recommendations for Practice (second edition) Guide to Breast Care for Oncology Nurses Guide to Cancer Immunotherapy (second edition) ONS courses: ONS Fundamentals of Chemotherapy and Immunotherapy Administration™ ONS/ONCC® Chemotherapy Immunotherapy Certificate™ Clinical Journal of Oncology Nursing article: Antibody–Drug Conjugates and Ocular Toxicity: Nursing, Patient, and Organizational Implications for Care The Association Between Hormone Receptor Status and End-of-Life Care Among Patients With Metastatic Breast Cancer Oncology Nursing Forum article: Impact of Race and Area Deprivation on Triple-Negative Metastatic Breast Cancer Outcomes ONS huddle cards: Altered Body Image Huddle Card Chemotherapy Huddle Card Targeted Therapy Huddle Card Foundations of Antibody–Drug Conjugate Use in Metastatic Breast Cancer: A Case Study ONS Biomarker Database (refine by breast cancer) ONS Breast Cancer Learning Library American Society of Clinical Oncology (ASCO) homepage Drugs@FDA package inserts National Comprehensive Cancer Network homepage Susan G. Komen metastatic breast cancer page To discuss the information in this episode with other oncology nurses, visit the ONS Communities.  To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode "What an ADC is doing is taking the antibody and linking it to a cytotoxic chemotherapy with the idea of delivering it directly into the cell. How I explain this to new nurses or patients is a backpack analogy. If we think of it as a HER2 molecule wearing a chemo backpack, it's going to find the HER2 receptor attached to it and then drop the chemotherapy into the cell via the backpack. Similar to how we come home from work, we open the key to our door, we're carrying all of our items, and then we drop our own personal items in our house." TS 2:30 "The reason that so many patients with metastatic breast cancer are able to receive ADC therapy is because they are targeting two very common antibodies that we see in breast cancer. One is HER2 and the other is trophoblast cell surface antigen 2 (TROP2). These are seen across the board. We see these on triple-negative breast cancers, hormone receptor–positive cancers, and HER2-positive breast cancers. And now we have a new way to talk about HER2, which is a HER2-low. ... Recently, we have found that patients who express low levels of HER2 are able to receive ADC therapy, specifically fam-trastuzumab deruxtecan." TS 4:21 "Another [ADC] that has just been approved is datopotamab deruxtecan. This is another ADC that targets the TROP2 receptor on a cancer cell. This one carries a lot of side effects. I mentioned earlier that you need an ophthalmology clearance because there is a lot of ocular toxicity around this one. We see a lot of blepharitis, conjunctivitis, there can be blurred vision. Another thing we monitor on this one is mucositis. In the package insert, there's a recommendation for using ice chips while receiving the treatment. ... Then in the HER2-positive and HER2-low space is the big one, which is fam-trastuzumab deruxtecan. This was approved in 2019 for the HER2-positive patients, then more recently in the HER2-low [patients]. The big [side effect] with this one is interstitial lung disease." TS 10:11 "Interstitial lung disease is an inflammation or a little bit of fibrosis within the lung that causes an impaired exchange between the oxygen and carbon dioxide. This was seen in the clinical trials, specifically around fam-trastuzumab deruxtecan. During the trials, they had a very small percentage, I think it was 1%, that died due to interstitial lung disease. So, this is a very important side effect for us as nurses to be aware of. It typically presents in patients like a dyspnea. A lot of times, it's like, 'Well, I used to be able to walk my kid to the bus stop, but now when I walk there, I feel really short of breath.' Or 'I've had this dry cough for the past couple weeks and I've tried medications, but haven't had that relieved.' So, we really need to be aware of that because early intervention in interstitial lung disease is key." TS 12:57 "ADCs are toxic drugs. They have the benefit of being targeted, but we know that they carry a lot of side effects. ... Their specificity makes them so wonderful and we've seen amazing responses to these drugs. But also, we want patients to be safe. We want to give these drugs safely. So, we have to assess our patients and make sure that this is an appropriate patient to give this therapy to. I think that's an open conversation that clinicians need to have with patients regarding these drugs." TS 18:08

We are entering an era of holistic health and well-being that transcends former ways holistic health was taught. This means that it also involves financial well-being, our faith and spirituality, and honoring that different belief systems can overlap and are available to us. We can use discernment in which belief systems apply to our optimal well-being. This is an era of science and alternative healing -- using the intertwining of ancient wisdom with modern medicine to create an empowering approach that is unique and applicable to each and every individual. Tune in as we dive into these topics and share our personal journeys through conversation with Beena Patel. She is the Founder of The Yoga Movement and a licensed Physician Associate, Yoga Teacher, Reiki Healer, and Health Coach. With clinical training from top academic institutions such as Columbia University Medical Center and Memorial Sloan Kettering Cancer Center, she blends modern medicine with ancient wisdom to help high-achieving women and organizations shift from burnout to deep alignment. Through her transformative coaching and healing work, Beena empowers clients to reclaim their health, purpose, and legacy—bridging science and soul for lifelong impact. Connect with Beena via: Email: beena@theyogamovementnyc.com  Website: The Yoga Movement FB: theyogamovement IG: @theyogamovement  YT: @theyogamovementnyc

Guest: Dr. Thomas Vierbuchen is Assistant Professor of Developmental Biology at Memorial Sloan Kettering Cancer Center. In this episode, he talks about using PSCs to model neurodevelopmental processes. He also discusses his direct reprogramming work and his lab’s recent study on OTX2 in gastrulation. (42:02) Featured Products and Resources: Submit your abstract for ISSCR 2026! Explore STEMCELL Technologies’ collection of technical videos and webinars on neurological disease modeling. The Stem Cell Science Round Up Restoring Function After Spinal Cord Injury: In a non-human primate model of spinal injury, researchers grafted ESC-derived spinal cord neural stem cells and improved forelimb function. (2:00) Improving HSC Expansion: Inhibiting ferroptosis augments the expansion of HSCs ex vivo. (11:40) Cardiomyocytes and Macrophage Reprogramming: Injury-induced Clusterin+ cardiomyocytes promote neonatal heart regeneration by reprogramming macrophages. (21:27) Bone Marrow Organoids: A 3D in vitro bone marrow model captures phenotypic, structural, and functional features of human endosteal bone marrow niches. (33:03) Image courtesy of Dr. Thomas Vierbuchen Subscribe to our newsletter! Never miss updates about new episodes. Subscribe

Candice Kumai's Art of Eating Well: The Forgotten Secret to Beauty, Health & Longevity We live in an era obsessed with optimization — trackers, injections, powders, and pills — yet we've never been more sick, anxious, or disconnected from what truly nourishes us. In this episode, I return to the foundation of real wellness: fiber-rich, whole, beautiful food. Inspired by Dr. Urvi Shah's groundbreaking research at Memorial Sloan Kettering Cancer Center — showing how a plant-based, high-fiber diet can help prevent and slow disease — I share how eating well is the most powerful act of self-respect and healing. This is your reminder to come back to the kitchen, the cutting board, and the joy of cooking real food. The art of eating well is the art of living beautifully. Thank you for listening xx Share this podcast with a few girlfriends and write a five star review! Be good to you xx x ck